Anixa Biosciences的乳腺癌疫苗在福克斯新闻的“美国报道”中被重点介绍-动脉网

Anixa Biosciences' Breast Cancer Vaccine was Featured on Fox News' "America Reports"

Anixa 等信源发布 2025-02-25 07:30



可切换为仅中文







SAN JOSE, Calif.

加利福尼亚州圣何塞

，

Feb. 25, 2025

2025年2月25日

/PRNewswire/ --

/美通社/ --

Anixa Biosciences, Inc.

安尼萨生物科学公司

('Anixa' or the 'Company') (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its breast cancer vaccine was featured on Fox News' 'America Reports.' The segment highlighted the potential of Anixa's vaccine to revolutionize breast cancer prevention by targeting the disease at its earliest stages..

('Anixa'或'公司')（纳斯达克股票代码：ANIX），一家专注于癌症治疗和预防的生物技术公司，今天宣布其乳腺癌疫苗在福克斯新闻的《美国报道》中被重点介绍。该节目强调了Anixa疫苗通过在乳腺癌最早阶段进行干预，有潜力彻底改变乳腺癌预防的前景。

Anixa's breast cancer vaccine is designed to train the immune system to recognize and eliminate cancerous cells before they can develop into invasive tumors. The vaccine targets a lactation protein, α-lactalbumin, which is only expressed in the breast when a woman is lactating but not at other times in her life or in other tissues.

Anixa的乳腺癌疫苗旨在训练免疫系统识别并消除癌细胞，防止其发展为侵袭性肿瘤。该疫苗针对一种泌乳蛋白α-乳白蛋白，这种蛋白仅在女性哺乳时在乳腺中表达，而在其生命中的其他时期或其他组织中不表达。

However, when a woman develops breast cancer, including TNBC or other types of breast cancer, many of the malignant cells will express α-lactalbumin. Activating the immune system, through vaccination, to direct cytotoxic T cells to the tumor cell expressing this protein may provide preemptive immune protection against emerging breast tumors that express α-lactalbumin..

然而，当女性患上乳腺癌，包括三阴性乳腺癌（TNBC）或其他类型的乳腺癌时，许多恶性细胞会表达α-乳白蛋白。通过疫苗接种激活免疫系统，引导细胞毒性T细胞针对表达该蛋白的肿瘤细胞，可能为表达α-乳白蛋白的新兴乳腺肿瘤提供预先的免疫保护。

'We are pleased to have our breast cancer vaccine featured on Fox News' 'America Reports,' as this national exposure brings greater awareness to the importance of preventative cancer immunotherapy,' said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. 'We believe we have made significant strides, and we are optimistic about the impact this vaccine could have in reducing the incidence of triple-negative breast cancer as well as other breast cancers.'.

“我们很高兴我们的乳腺癌疫苗能在福克斯新闻的《美国报道》中亮相，因为这种全国性的曝光提高了人们对预防性癌症免疫疗法重要性的认识，”Anixa Biosciences董事长兼首席执行官阿米特·库马尔博士说。“我们相信我们已经取得了重大进展，我们对这种疫苗在降低三阴性乳腺癌及其他乳腺癌发病率方面可能产生的影响感到乐观。”

The Phase I clinical trial, conducted in collaboration with Cleveland Clinic and funded by a grant from the U.S. Department of Defense, continues to show promising progress. As additional patients are enrolled across all three cohorts, Anixa is encouraged by the positive data trends emerging. The vaccine has demonstrated a strong safety profile, being well tolerated by participants, with protocol-defined immune responses observed in over 70% of patients.

与克利夫兰诊所合作开展并由美国国防部拨款资助的第一阶段临床试验继续显示出良好的进展。随着所有三个队列中更多患者入组，Anixa 对出现的积极数据趋势感到鼓舞。该疫苗表现出良好的安全性，参与者耐受性良好，在超过 70% 的患者中观察到方案定义的免疫反应。

Looking ahead, a Phase 2 study in the neoadjuvant setting is planned to begin in 2025, representing a critical milestone in the vaccine's continued development..

展望未来，计划于2025年开始在新辅助治疗环境中进行的二期研究，这代表了该疫苗持续开发过程中的一个关键里程碑。

To watch the Fox News 'America Reports' feature, please visit Anixa's YouTube channel:

要观看福克斯新闻的《美国报道》专题，请访问Anixa的YouTube频道：

https://www.youtube.com/watch?v=PIvp5oiK-Ac

。

About Anixa Biosciences, Inc.

关于Anixa生物科学公司

Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology.

Anixa是一家临床阶段的生物技术公司，专注于癌症的治疗和预防。Anixa的治疗产品组合包括与莫菲特癌症中心合作开发的卵巢癌免疫疗法项目，该项目采用一种新型CAR-T，即嵌合内分泌受体T细胞（CER-T）技术。

The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate.

公司的疫苗组合包括与克利夫兰诊所合作开发的用于治疗和预防乳腺癌和卵巢癌的疫苗，以及针对许多难治性癌症的其他癌症疫苗，包括肺、结肠和前列腺的高发恶性肿瘤。

These vaccine technologies focus on immunizing against 'retired' proteins that have been found to be expressed in certain forms of cancer. Anixa's business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization.

这些疫苗技术专注于免疫某些已被发现会在特定形式的癌症中表达的“退役”蛋白质。Anixa 的商业模式是与世界知名的研究机构在开发的各个阶段进行合作，这使得公司能够不断审视互补领域中的新兴技术，以进一步开发和商业化。

To learn more, visit .

要了解更多信息，请访问。

www.anixa.com

or follow Anixa on

或关注Anixa

Twitter

，

领英

，

Facebook

脸书

and

和

YouTube

。

Forward-Looking Statements

前瞻性声明

Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results.

非历史事实的陈述可能被视为1995年《私人证券诉讼改革法案》意义上的前瞻性陈述。前瞻性陈述并非历史事实的陈述，而是反映Anixa对未来事件和结果的当前预期。

We generally use the words 'believes,' 'expects,' 'intends,' 'plans,' 'anticipates,' 'likely,' 'will' and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.

我们通常使用“相信”、“预期”、“打算”、“计划”、“预计”、“可能”、“将”等词语以及类似表述来识别前瞻性声明。这些前瞻性声明，包括关于我们预期的声明，涉及风险、不确定性和其他因素，其中一些因素超出我们的控制范围，可能导致我们的实际结果、表现或成就，或者行业结果，与这些前瞻性声明明示或暗示的任何未来结果、表现或成就存在重大差异。

These risks, uncertainties and factors include, but are not limited to, those factors set forth in 'Item 1A - Risk Factors' and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

这些风险、不确定性和因素包括但不限于我们最近的年度报告Form 10-K中的“第1A项 - 风险因素”及其他章节，以及我们的季度报告Form 10-Q和当前报告Form 8-K中列出的因素。我们没有义务公开更新或修改任何前瞻性陈述，无论是由于新信息、未来事件或其他原因，除非法律要求。

You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release..

您在评估本新闻稿中提供的信息时，应注意不要过分依赖这些前瞻性陈述。

Contact:

联系人：

Mike Catelani

迈克·卡特兰尼

President, COO & CFO

总裁、首席运营官和首席财务官

mcatelani@anixa.com

408-708-9808

View original content to download multimedia: